DengiAll, which is Panacea Biotec's tetravalent live-attenuated vaccine, uses weakened strains of all four DENV serotypes. As ...
Takeda’s dengue fever vaccine Qdenga has demonstrated its long-term benefits against infection and hospitalisation in a Phase III trial. During the TIDES study (NCT02747927), two doses of the live, ...
Dengue infects up to 400 million people and kills thousands every year but an Indian company is now inching closer to a ...
As dengue surges globally, an Indian vaccine candidate has entered the final stage of testing, raising hopes for one of the ...
PARIS, July 11 (Reuters) - The first vaccine against dengue fever, from France's Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help fight ...
The first vaccine formulated to combat dengue fever, a virus spread by the same mosquito responsible for Zika, has launched in the Philippines, according to a CNN report. Dengue fever infects nearly ...
The vaccine to be considered for introduction in settings with high dengue disease burden and high transmission intensity to maximize the public health impact and minimize any potential risk in ...
A new vaccine and an antiviral treatment for dengue fever are being hailed as breakthroughs in the global fight against the mosquito-borne disease. The one-dose vaccine, which has been approved for ...
Dengue fever caused by a flavivirus named DENV is a major global health challenge, risking almost half of the world's population. Since the early 20 th century, the scientific community has faced ...
Indian company nears dengue vaccine breakthrough - ...
BANGKOK, June 10 (Reuters) - The world's first efficacy trial of a dengue fever vaccine being developed by France's Sanofi Pasteur and due for release in 2014 has seen "very promising" results in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results